The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
Jing Pu,Qin Yu,Zhifang Yin,Ying Zhang,Xueqi Li,Qiongzhou Yin,Hongbo Chen,Runxiang Long,Zhimei Zhao,Tangwei Mou,Heng Zhao,Shiyin Feng,Zhongping Xie,Lichun Wang,Zhanlong He,Yun Liao,Shengtao Fan,Ruiju Jiang,Jianfeng Wang,Lingli Zhang,Jing Li,Huiwen Zheng,Pingfang Cui,Guorun Jiang,Lei Guo,Mingjue Xu,Huijuan Yang,Shan Lu,Xuan-Yi Wang,Yang Gao,Xingli Xu,Linrui Cai,Jian Zhou,Li Yu,Zhuo Chen,Chao Hong,Dan Du,Hongling Zhao,Yan Li,Kai-Li Ma,Yunfei Ma,Donglan Liu,Shibao Yao,Changgui Li,Yanchun Che,Longding Liu,Qihan Li +46 more
TLDR
In a phase I randomized, double-blinded, placebo-controlled trial involving 192 healthy adults 18-59 years old, two injections of three doses (50 EU, 100 EU, 150 EU) of an inactivated SARS-CoV-2 vaccine or placebo were administered intramuscularly at a 2- or 4-week interval as discussed by the authors.About:
This article is published in Vaccine.The article was published on 2021-05-12 and is currently open access. It has received 37 citations till now. The article focuses on the topics: Immunogenicity & Vaccination.read more
Citations
More filters
Journal ArticleDOI
Evaluation of the safety profile of COVID-19 vaccines: a rapid review.
Qianhui Wu,Matthew Z. Dudley,Xinghui Chen,Xufang Bai,Kaige Dong,Tingyu Zhuang,Daniel A. Salmon,Hongjie Yu +7 more
TL;DR: In this article, a comprehensive overview of the safety profile of COVID-19 vaccines by using meta-analysis technique was provided by using PubMed, Embase, Web of Science, PMC, official regulatory websites, and post-authorization safety surveillance data.
Journal ArticleDOI
Administration of COVID-19 vaccines in immunocompromised patients.
Manica Negahdaripour,Mojtaba Shafiekhani,Seyed Mohammad Iman Moezzi,Sogand Amiri,Shiva Rasekh,Ashkan Bagheri,Pouria Mosaddeghi,Afsaneh Vazin +7 more
TL;DR: In this article, a review of the available COVID-19 vaccines, considerations and available knowledge about administering similar vaccines in patients with cancer, hematopoietic stem cell transplant, solid organ transplantation, multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatologic and dermatologic autoimmune disorders are summarized to help in decision making.
Journal ArticleDOI
An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
Saeed Khoshnood,Maniya Arshadi,Sousan Akrami,M Kharati Koupaei,Hossein Ghahramanpour,Aref Shariati,Nourkhoda Sadeghifard,Mohsen Heidary +7 more
TL;DR: This study has a review on inactivated SARS‐CoV‐2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.
Journal ArticleDOI
A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders
Farnoosh Seirafianpour,Homa Pourriyahi,M. Mesgarha,Arash Pour Mohammad,Zoha Shaka,Azadeh Goodarzi +5 more
TL;DR: Based on the findings, mucocutaneous adverse events were mostly non‐significant, self‐limiting reactions, and for the more uncommon moderate to severe reactions, guidelines and consensus position papers could be of great importance to provide those at higher risks and those with specific worries of flare‐ups or inefficient immunization with sufficient recommendations to safely schedule their vaccine doses, or avoid vaccination if they have the discussed contra‐indications.
Journal ArticleDOI
Efficacy and safety of COVID-19 vaccines
TL;DR: In this paper , the authors evaluated the efficacy and safety of COVID-19 vaccines against SARS-CoV•2 virus and concluded that they probably reduce the risk of all-cause mortality (risk ratio (RR) 0.25, 95% CI 0.09 to 0.67.
References
More filters
Journal ArticleDOI
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Jun Lan,Jiwan Ge,Jinfang Yu,Sisi Shan,Huan Zhou,Shilong Fan,Qi Zhang,Xuanling Shi,Qisheng Wang,Linqi Zhang,Xinquan Wang +10 more
TL;DR: High-resolution crystal structures of the receptor-binding domain of the spike protein of SARS-CoV-2 and SARS -CoV in complex with ACE2 provide insights into the binding mode of these coronaviruses and highlight essential ACE2-interacting residues.
Journal ArticleDOI
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson,Evan J. Anderson,Nadine Rouphael,Paul C. Roberts,Mamodikoe Makhene,Rhea N. Coler,Michele Paine McCullough,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Nicole A. Doria-Rose,Kizzmekia S. Corbett,Kaitlyn M. Morabito,Sijy O’Dell,Stephen D. Schmidt,Phillip A. Swanson,Marcelino Padilla,John R. Mascola,Kathleen M. Neuzil,Hamilton Bennett,Wellington Sun,Etza Peters,Mat Makowski,Jim Albert,Kaitlyn Cross,Wendy Buchanan,Rhonda Pikaart-Tautges,Julie E. Ledgerwood,Barney S. Graham,John H. Beigel +32 more
TL;DR: The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Journal ArticleDOI
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
P M Folegatti,Katie J. Ewer,Parvinder K. Aley,Brian Angus,Stephan Becker,Sandra Belij-Rammerstorfer,D Bellamy,S Bibi,M Bittaye,Elizabeth A. Clutterbuck,Christina Dold,Saul N. Faust,Adam Finn,Amy Flaxman,Bassam Hallis,Paul T. Heath,D Jenkin,Rajeka Lazarus,R Makinson,Angela M. Minassian,Katrina M Pollock,M N Ramasamy,Hannah Robinson,Matthew D. Snape,R Tarrant,Merryn Voysey,Catherine M. Green,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +31 more
TL;DR: A phase 1/2, single-blind, randomized controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control was conducted.
Journal ArticleDOI
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Mark J. Mulligan,Kirsten E. Lyke,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen M. Neuzil,Vanessa Raabe,Ruth Bailey,Kena A. Swanson,Ping Li,Kenneth Koury,Warren Kalina,David A. Cooper,Camila R. Fontes-Garfias,Pei Yong Shi,Özlem Türeci,Tompkins Kristin Rachael,Edward E. Walsh,Edward E. Walsh,Robert W. Frenck,Ann R. Falsey,Ann R. Falsey,Philip R. Dormitzer,William C. Gruber,Ugur Sahin,Kathrin U. Jansen +26 more
TL;DR: In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Feng Cai Zhu,Yu-Hua Li,Xu Hua Guan,Li Hua Hou,Wen-Juan Wang,Jing Xin Li,Shi Po Wu,Bu Sen Wang,Zhao Wang,Lei Wang,Si Yue Jia,Hu Dachuan Jiang,Ling Wang,Tao Jiang,Yi Hu,Jin Bo Gou,Sha Bei Xu,Jun-Jie Xu,Xue-Wen Wang,Wei Wang,Wei Chen +20 more
TL;DR: A dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain to assess the safety, tolerability, and immunogenicity.
Related Papers (5)
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Shengli Xia,Kai Duan,Yuntao Zhang,Dongyang Zhao,Huajun Zhang,Zhiqiang Xie,Xinguo Li,Cheng Peng,Yan-Bo Zhang,Wei Zhang,Yunkai Yang,Wei Chen,Xiaoxiao Gao,Wangyang You,Xue-Wei Wang,Zejun Wang,Zhengli Shi,Y. Wang,Xuqin Yang,Lianghao Zhang,Lili Huang,Qian Wang,Jia Lu,Yongli Yang,Jing Guo,Wei Zhou,Xin Wan,Cong Wu,Wenhui Wang,Shihe Huang,Du Jianhui,Ziyan Meng,An Pan,Zhiming Yuan,Shuo Shen,Wanshen Guo,Xiaoming Yang +36 more
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Feng Cai Zhu,Xu Hua Guan,Yu-Hua Li,Jian Ying Huang,Tao Jiang,Li Hua Hou,Jing Xin Li,Bei Fang Yang,Ling Wang,W J Wang,Shi Po Wu,Zhao Wang,Xiao Hong Wu,Jun Jie Xu,Zhe Zhang,Si Yue Jia,Bu Sen Wang,Yi Hu,Jing Jing Liu,Jun Zhang,Xiao Ai Qian,Qiong Li,Hong Xing Pan,Hu Dachuan Jiang,Peng Deng,Jin Bo Gou,Xue-Wen Wang,Xing Huan Wang,Wei Chen +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
P M Folegatti,Katie J. Ewer,Parvinder K. Aley,Brian Angus,Stephan Becker,Sandra Belij-Rammerstorfer,D Bellamy,S Bibi,M Bittaye,Elizabeth A. Clutterbuck,Christina Dold,Saul N. Faust,Adam Finn,Amy Flaxman,Bassam Hallis,Paul T. Heath,D Jenkin,Rajeka Lazarus,R Makinson,Angela M. Minassian,Katrina M Pollock,M N Ramasamy,Hannah Robinson,Matthew D. Snape,R Tarrant,Merryn Voysey,Catherine M. Green,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +31 more